Ikarian Capital, LLC Bridge Bio Pharma, Inc. Transaction History

Ikarian Capital, LLC

$573 Million
Q3 2024

A detailed history of Ikarian Capital, LLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 285,613 shares of BBIO stock, worth $6.77 Million. This represents 1.27% of its overall portfolio holdings.

Number of Shares

285,613

Previous 6,000 4660.22%

Holding current value

$6.77 Million

Previous $151,000 4715.23%

% of portfolio

1.27%

Previous 0.06%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$23.91 - $31.3 $1.11 Million - $1.45 Million	-46,400 Reduced 13.98%	285,613 $7.27 Million
Q2 2024 Aug 14, 2024	BUY	$23.0 - $31.04 $1.15 Million - $1.55 Million	50,000 Added 17.73%	332,013 $8.41 Million
Q1 2024 May 15, 2024	SELL	$27.35 - $40.45 $5.23 Million - $7.73 Million	-191,113 Reduced 40.39%	282,013 $8.72 Million
Q3 2023 Nov 14, 2023	BUY	$16.89 - $35.01 $733,701 - $1.52 Million	43,440 Added 10.11%	473,126 $12.5 Million
Q2 2023 Aug 14, 2023	SELL	$13.29 - $18.01 $2.19 Million - $2.97 Million	-165,000 Reduced 27.75%	429,686 $7.39 Million
Q1 2023 May 15, 2023	BUY	$7.17 - $18.55 $4.26 Million - $11 Million	594,686 New	594,686 $9.86 Million
Q1 2022 May 13, 2022	SELL	$7.34 - $17.16 $11,010 - $25,740	-1,500 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$11.38 - $53.41 $983,232 - $4.61 Million	-86,400 Reduced 98.29%	1,500 $25,000
Q1 2020 May 15, 2020	BUY	$16.11 - $36.23 $1.42 Million - $3.18 Million	87,900 New	87,900 $2.55 Million

Others Institutions Holding BBIO

# of Institutions

291

Shares Held

171M

Call Options Held

10.4M

Put Options Held

2.37M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $3.52B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Account

Ikarian Capital, LLC Bridge Bio Pharma, Inc. Transaction History